In parallel, Holmen, a leading manufacturer in the forest based sector, has entered into an investment and sub-licensing agreement with Melodea, by which Holmen has become one of the major shareholders in Melodea.
The capital is intended for the on-going Phase II clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; interim analysis is expected in H1 2014
Yissum, introduces new chickpea varieties, which retain high nutritional values yet exhibit improved synchronization between flowering and the rainy season to increase yield. The new varieties were developed by Professor Shahal Abbo, The Robert H. Smith Institute of Plant Sciences and Genetics in Agriculture, Robert H. Smith Faculty of Agriculture, Food and Environment at the Hebrew University.
Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine
Integra Holdings closes U.S. $ 7.0 million private financing
Novel biocontrol agent is environmentally-friendly, non-toxic and effective for a large variety of plants
The novel method uses a peptide derived from HIV to increase the sensitivity of cancer cells to radiotherapy and chemotherapy
Yaacov Michlin appointed Chairman of the Board and Dr. Yona Geffen appointed Chief Executive Officer
Technology, to be presented at Agritech Israel 2012, enables better control over fish reproduction cycle, increasing spawning and fish size
Yissum, the research and development company of the Hebrew University of Jerusalem, North Carolina State University, Raleigh , N.C., and Dow AgroFresh, a business unit of Rohm and Haas Company, a wholly owned subsidiary of The Dow Chemical Company, signed a license agreement for the development and commercialization of a novel water-soluble ethylene-antagonist for agricultural applications.
Atox Bio will be included as one of the portfolio companies of Integra Holdings, a holding company currently formed by Yissum, the technology transfer company of the Hebrew University of Jerusalem.
The work was published in the latest issue of the prestigious Nature Biotechnology journal
Technology to be presented at WATEC, the Water Technologies, Renewable Energy and Environmental Control Exhibition and Conference
Yissum will now maintain 30% holding share in Avraham Pharmaceuticals, which will be transferred to its forthcoming biotech holdings company
The novel technology has been proven effective in a number of plant species
The first research funded focuses on forecasting of car sales
BL-7040 has dual activity on both the nervous and immune systems, rendering it highly suitable for treating both neurological diseases and immune system related conditions such as inflammatory or autoimmune diseases. It was invented by HUJI Professor Hermona Soreq.
Prof. Haim Rabinowitch, Prof. Dan Gazit and Dr. Raanan Fattal were all awarded the prestigious Kaye Award which is dedicated to encourage faculty, staff, and students of the Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society.
The device was presented for the 1st time at the Israeli Presidential Conference, which is held in collaboration with the Hebrew University of Jerusalem
Prof. Haim Rabinowitch, Prof. Dan Gazit and Dr. Raanan Fattal were all awarded the prestigious Kaye Award which is dedicated to encourage faculty, staff, and students of the Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society.
